首页> 外文期刊>Cancer letters >Rapid on-site evaluation during endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of hilar and mediastinal lymphadenopathy in patients with lung cancer
【24h】

Rapid on-site evaluation during endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of hilar and mediastinal lymphadenopathy in patients with lung cancer

机译:在肺癌患者诊断肺癌患者诊断期间,在内核超声引导的跨界针头的快速现场评价患者诊断肺癌患者的诊断和纵隔淋巴结病

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to assess the usefulness of rapid on-site evaluation (ROSE) during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and the interpretation of its results. Based on the criterion of using ROSE or not, 236 patients with known or suspected lung cancer undergoing EBUS-TBNA were allocated into the ROSE group (122 patients with 252 lymph nodes) and non-ROSE group (114 patients with 260 lymph nodes). In the ROSE group, the percentages of the suspicious specimens on cytology and non-diagnostic specimens on pathology were both significantly lower than that in the non-ROSE group (8.7% vs. 14.6%, p = 0.038; and 0.9% vs. 4.4%, p = 0.018, respectively), and 13 out of 22 suspicious lesions on ROSE were confirmed with definite diagnoses on TBNA pathology. The diagnostic yield stratified by pathology was significantly higher in the ROSE group than that in the non ROSE group (90.5% vs. 81.2%, p = 0.003). These results suggest that ROSE during EBUS-TBNA allows for a low rate of suspicious results and therefore improves the diagnostic yield stratified by pathology when sampling hilar or mediastinal lymphadenopathy in patients with lung cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
机译:本研究的目的是评估在内核超声引导的横向针刺(EBUS-TBNA)期间快速现场评估(玫瑰)的有用性以及对结果的解释。基于使用玫瑰的标准,236名患有EBUS-TBNA的已知或疑似肺癌患者分配到玫瑰组(122例252例淋巴结患者)和非玫瑰组(114例淋巴结患者)中。在玫瑰集团中,细胞学和非诊断标本对病理学的可疑标本的百分比显着低于非玫瑰基团(8.7%对14.6%,P = 0.038;和0.9%Vs.4分别,P = 0.018分别为22种可疑病变的13例,并在TBNA病理学上确认了玫瑰上的13个。玫瑰基团的病理分层分层的诊断产量显着高于非玫瑰基团(90.5%vs.81.2%,P = 0.003)。这些结果表明,EBUS-TBNA期间玫瑰允许低速率可疑结果,因此在肺癌患者中采样患者或纵隔淋巴结病时,提高了病理分层的诊断产量。 (c)2015 Elsevier Ireland Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号